Dr. Andrew T. Chan is Chief of the Clinical and Translational Epidemiology Unit (CTEU) at Massachusetts General Hospital (MGH), Director of Cancer Epidemiology at the MGH Cancer Center, Professor of Medicine at Harvard Medical School (HMS), and Professor of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health. He also co-leads the Cancer Epidemiology Program at the Dana-Farber Harvard Cancer Center. His research broadly aims to advance epidemiological investigation for the translation of discoveries into effective clinical interventions. His current focus is on chronic digestive diseases, including gastrointestinal cancer (colorectal, esophageal, gastric), inflammatory bowel disease, diverticulitis, and gastrointestinal bleeding. His group utilizes molecular approaches encompassing genetic, metabolomic, proteomic, and biochemical platforms applied to populations ranging from large cohort studies to small biomarker-driven clinical trials. He also has an active program studying the oral and gut microbiome as a determinant and mediator of chronic disease.
Dr. Chan earned his MD from Harvard Medical School and a MPH from Harvard T.H. Chan School of Public Health. He completed his internal medicine residency, chief residency, and gastroenterology fellowship at MGH. He is the Stuart and Suzanne Steele MGH Research Scholar. He is an Elected Fellow of the American Society of Clinical Investigation. His work is supported by grants from the National Cancer Institute, the National Institute for Diabetes, Digestive and Kidney Diseases, the National Institutes of Aging, Stand Up to Cancer, Cancer Research UK, the Crohn’s and Colitis Foundation, and the Damon Runyon Cancer Research Foundation. He is chair of the GI Oncology section of the American Gastroenterological Association Council and the Molecular Epidemiology Group of the American Association for Cancer Research.
